SENSEX NIFTY
Jan 01, 2013, 05.32 PM IST | Source: Moneycontrol.com

Aurobindo closes up 2% on approvals for Rizatriptan

Healthcare firm Aurobindo Pharma rose 2.11 percent to close at Rs 193.30 on the Bombay Stock Exchange on Tuesday as the company has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate Tablets.

Healthcare firm Aurobindo Pharma rose 2.11 percent to close at Rs 193.30 on the Bombay Stock Exchange on Tuesday as the company has received final approval from the US Food & Drug Administration to manufacture and market Rizatriptan Benzoate Tablets.

The company said the product was ready for launch. "Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) is the generic equivalent of Merck and company's Maxalt tablets and is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 6 to 17 years old," Aurobindo said in a release.

The annual sale of product is approximately USD 300 million for 12 months ending March 2012, according to IMS. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad.

Aurobindo has a total of 171 ANDA approvals from USFDA.

Also Read
M&M Dec auto sales up 6% to 45,297 units
Etihad board to consider investment in Kingfisher, Jet

Aurobindo Pharm stock price

On July 28, 2014, Aurobindo Pharma closed at Rs 679.00, down Rs 14.3, or 2.06 percent. The 52-week high of the share was Rs 786.50 and the 52-week low was Rs 138.45.


The company's trailing 12-month (TTM) EPS was at Rs 40.21 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 16.89. The latest book value of the company is Rs 141.06 per share. At current value, the price-to-book value of the company is 4.81.

READ MORE ON  Aurobindo Pharma
Set email alert for

ADS BY GOOGLE

video of the day

Positive on PSU banks; NPA cycle may have peaked: Barclays

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.